These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
432 related articles for article (PubMed ID: 27655724)
1. Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors. Mei Y; Bi WL; Greenwald NF; Du Z; Agar NY; Kaiser UB; Woodmansee WW; Reardon DA; Freeman GJ; Fecci PE; Laws ER; Santagata S; Dunn GP; Dunn IF Oncotarget; 2016 Nov; 7(47):76565-76576. PubMed ID: 27655724 [TBL] [Abstract][Full Text] [Related]
2. The Progress of Immunotherapy in Refractory Pituitary Adenomas and Pituitary Carcinomas. Dai C; Liang S; Sun B; Kang J Front Endocrinol (Lausanne); 2020; 11():608422. PubMed ID: 33362722 [TBL] [Abstract][Full Text] [Related]
3. The expression profile of PD-L1 and CD8 Wang PF; Wang TJ; Yang YK; Yao K; Li Z; Li YM; Yan CX J Neurooncol; 2018 Aug; 139(1):89-95. PubMed ID: 29680903 [TBL] [Abstract][Full Text] [Related]
4. MSH6/2 and PD-L1 Expressions Are Associated with Tumor Growth and Invasiveness in Silent Pituitary Adenoma Subtypes. Uraki S; Ariyasu H; Doi A; Takeshima K; Morita S; Inaba H; Furuta H; Fukuhara N; Inoshita N; Nishioka H; Nakao N; Yamada S; Akamizu T Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32325698 [TBL] [Abstract][Full Text] [Related]
5. Comprehensive analysis of the immunological landscape of pituitary adenomas: implications of immunotherapy for pituitary adenomas. Zhou W; Zhang C; Zhang D; Peng J; Ma S; Wang X; Guan X; Li P; Li D; Jia G; Jia W J Neurooncol; 2020 Sep; 149(3):473-487. PubMed ID: 33034841 [TBL] [Abstract][Full Text] [Related]
6. The Upregulation of Molecules Related to Tumor Immune Escape in Human Pituitary Adenomas. Xi Z; Jones PS; Mikamoto M; Jiang X; Faje AT; Nie C; Labelle KE; Zhou Y; Miller KK; Soberman RJ; Zhang X Front Endocrinol (Lausanne); 2021; 12():726448. PubMed ID: 34745002 [TBL] [Abstract][Full Text] [Related]
7. Targeting PD-L1 Initiates Effective Antitumor Immunity in a Murine Model of Cushing Disease. Kemeny HR; Elsamadicy AA; Farber SH; Champion CD; Lorrey SJ; Chongsathidkiet P; Woroniecka KI; Cui X; Shen SH; Rhodin KE; Tsvankin V; Everitt J; Sanchez-Perez L; Healy P; McLendon RE; Codd PJ; Dunn IF; Fecci PE Clin Cancer Res; 2020 Mar; 26(5):1141-1151. PubMed ID: 31744830 [TBL] [Abstract][Full Text] [Related]
8. Analysis of Cyclooxygenase 2, Programmed Cell Death Ligand 1, and Arginase 1 Expression in Human Pituitary Adenoma. Zhao G; Chen W; He J; Cui C; Zhao L; Zhao Y; Sun C; Nie D; Jin F; Kong L World Neurosurg; 2020 Dec; 144():e660-e673. PubMed ID: 32920160 [TBL] [Abstract][Full Text] [Related]
9. Expression of programmed death-ligand 1 (PD-L1) in human pituitary neuroendocrine tumor. Suteau V; Collin A; Menei P; Rodien P; Rousselet MC; Briet C Cancer Immunol Immunother; 2020 Oct; 69(10):2053-2061. PubMed ID: 32445029 [TBL] [Abstract][Full Text] [Related]
10. Specific expression of PD-L1 in RELA-fusion supratentorial ependymoma: Implications for PD-1-targeted therapy. Witt DA; Donson AM; Amani V; Moreira DC; Sanford B; Hoffman LM; Handler MH; Levy JMM; Jones KL; Nellan A; Foreman NK; Griesinger AM Pediatr Blood Cancer; 2018 May; 65(5):e26960. PubMed ID: 29350470 [TBL] [Abstract][Full Text] [Related]
11. Immune profiling of pituitary tumors reveals variations in immune infiltration and checkpoint molecule expression. Mei Y; Bi WL; Agolia J; Hu C; Giantini Larsen AM; Meredith DM; Al Abdulmohsen S; Bale T; Dunn GP; Abedalthagafi M; Dunn IF Pituitary; 2021 Jun; 24(3):359-373. PubMed ID: 33492612 [TBL] [Abstract][Full Text] [Related]
12. PD-L1 and tumor-infiltrating CD8 Shi M; Song Y; Zhang Y; Li L; Yu J; Hou A; Han S Front Endocrinol (Lausanne); 2023; 14():1151714. PubMed ID: 37424874 [TBL] [Abstract][Full Text] [Related]
13. Prognostic Value of Programmed Death Ligand 1 and Programmed Death 1 Expression in Thymic Carcinoma. Yokoyama S; Miyoshi H; Nakashima K; Shimono J; Hashiguchi T; Mitsuoka M; Takamori S; Akagi Y; Ohshima K Clin Cancer Res; 2016 Sep; 22(18):4727-34. PubMed ID: 27166394 [TBL] [Abstract][Full Text] [Related]
14. The Immune Profile of Pituitary Adenomas and a Novel Immune Classification for Predicting Immunotherapy Responsiveness. Wang Z; Guo X; Gao L; Deng K; Lian W; Bao X; Feng M; Duan L; Zhu H; Xing B J Clin Endocrinol Metab; 2020 Sep; 105(9):e3207-23. PubMed ID: 32652004 [TBL] [Abstract][Full Text] [Related]
15. The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors. Davis AA; Patel VG J Immunother Cancer; 2019 Oct; 7(1):278. PubMed ID: 31655605 [TBL] [Abstract][Full Text] [Related]
16. PD-L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung Cancer. Yu H; Batenchuk C; Badzio A; Boyle TA; Czapiewski P; Chan DC; Lu X; Gao D; Ellison K; Kowalewski AA; Rivard CJ; Dziadziuszko R; Zhou C; Hussein M; Richards D; Wilks S; Monte M; Edenfield W; Goldschmidt J; Page R; Ulrich B; Waterhouse D; Close S; Jassem J; Kulig K; Hirsch FR J Thorac Oncol; 2017 Jan; 12(1):110-120. PubMed ID: 27639678 [TBL] [Abstract][Full Text] [Related]
17. Biomarkers for PD-1/PD-L1 Blockade Therapy in Non-Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection? Chae YK; Pan A; Davis AA; Raparia K; Mohindra NA; Matsangou M; Giles FJ Clin Lung Cancer; 2016 Sep; 17(5):350-361. PubMed ID: 27137346 [TBL] [Abstract][Full Text] [Related]
18. Detection of programmed death ligand 1 protein and CD8+ lymphocyte infiltration in plurihormonal pituitary adenomas: A case report and review of the literatures. Wang P; Wang T; Yang Y; Yu C; Liu N; Yan C Medicine (Baltimore); 2017 Dec; 96(49):e9056. PubMed ID: 29245312 [TBL] [Abstract][Full Text] [Related]
19. Multiplexed immunofluorescence reveals potential PD-1/PD-L1 pathway vulnerabilities in craniopharyngioma. Coy S; Rashid R; Lin JR; Du Z; Donson AM; Hankinson TC; Foreman NK; Manley PE; Kieran MW; Reardon DA; Sorger PK; Santagata S Neuro Oncol; 2018 Jul; 20(8):1101-1112. PubMed ID: 29509940 [TBL] [Abstract][Full Text] [Related]
20. Enhanced B7-H4 expression in gliomas with low PD-L1 expression identifies super-cold tumors. Chen D; Li G; Ji C; Lu Q; Qi Y; Tang C; Xiong J; Hu J; Yasar FBA; Zhang Y; Hoon DSB; Yao Y; Zhou L J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32457124 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]